AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11179136 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 0
Study 11179136 — intervention group
Group type: COMPARATOR
Intervention: Negative pressure ventilation or abdominal displacement ventilators
Number of subjects: 0
Study 9154546 — intervention group
Group type: EXPERIMENTAL
Intervention: Torovirus antigen detection in children with acute diarrhea (n=33)
Number of subjects: 91
Study 9154546 — intervention group
Group type: EXPERIMENTAL
Intervention: Torovirus antigen detection in children with persistent diarrhea (n=41)
Number of subjects: 91
Study 9154546 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without diarrhea, n=17)
Number of subjects: 91
Study 9154546 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of enteroaggregative E. coli in children with persistent diarrhea
Number of subjects: 91
Study 9154546 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Cryptosporidium oocysts in children with diarrhea
Number of subjects: 91
Study 8201374 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrazine sulfate
Number of subjects: 243
Study 8201374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 3504454 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (0.5 mg) placed intracervically
Number of subjects: 0
Study 3504454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment prior to labor induction)
Number of subjects: 0
Study 31592387 — intervention group
Group type: EXPERIMENTAL
Intervention: dHACA (AmnioBand)
Number of subjects: 60
Study 31592387 — intervention group
Group type: COMPARATOR
Intervention: TESS (Apligraf)
Number of subjects: 60
Study 29281604 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins plus evolocumab
Number of subjects: 968
Study 29281604 — intervention group
Group type: COMPARATOR
Intervention: Statins alone
Number of subjects: 968
Study 25478758 — intervention group
Group type: EXPERIMENTAL
Intervention: TII SCB
Number of subjects: 64
Study 25478758 — intervention group
Group type: COMPARATOR
Intervention: ICB
Number of subjects: 64
Study 23480592 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued glimepiride
Number of subjects: 56
Study 23480592 — intervention group
Group type: COMPARATOR
Intervention: 50% reduced dose of metformin
Number of subjects: 56
Study 20535638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily (Group 1)
Number of subjects: 90
Study 20535638 — intervention group
Group type: COMPARATOR
Intervention: Rowatinex 100 mg capsules 3 times a day (Group 2)
Number of subjects: 90
Study 20535638 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 100 mg once daily (Group 3)
Number of subjects: 90
Study 19232658 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for malaria management
Number of subjects: 38
Study 19232658 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for leishmaniasis management
Number of subjects: 38
Study 19232658 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for lymphatic filariasis management
Number of subjects: 38
Study 19232658 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for schistosomiasis management
Number of subjects: 38
Study 17253883 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 0
Study 17253883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 0
Study 15817726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (12 microg.min(‐1).dl forearm(‐1))
Number of subjects: 26
Study 15817726 — intervention group
Group type: COMPARATOR
Intervention: Time-control study without dipyridamole
Number of subjects: 26
Study 15817726 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous intrabrachial infusion of dipyridamole and adenosine (100 microg.min(‐1).dl(‐1) dipyridamole and 5 microg.min(‐1).dl(‐1) adenosine)
Number of subjects: 26
Study 12213183 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 100
Study 12213183 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 100
Study 12213183 — intervention group
Group type: EXPERIMENTAL
Intervention: Funding source
Number of subjects: 100
Study 12213183 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality scores
Number of subjects: 100
Study 9863862 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily (qd) dosing of didanosine
Number of subjects: 19
Study 9863862 — intervention group
Group type: COMPARATOR
Intervention: Twice daily (bid) dosing of didanosine
Number of subjects: 19
Study 8520180 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin (two 400-micrograms doses intranasally 16 hours apart, followed by 7 more doses on LD6)
Number of subjects: 26
Study 8520180 — intervention group
Group type: COMPARATOR
Intervention: hCG (5000 IU intramuscularly on luteal day 0, followed by a single 2500 IU dose on LD6)
Number of subjects: 26
Study 8520180 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 26
Study 8520180 — intervention group
Group type: COMPARATOR
Intervention: hCG
Number of subjects: 26
Study 2090208 — intervention group
Group type: EXPERIMENTAL
Intervention: One single dose of 4 g piperacillin 30 minutes before surgery
Number of subjects: 93
Study 2090208 — intervention group
Group type: COMPARATOR
Intervention: Three doses of 4 g piperacillin (30 minutes before surgery, and 6 & 12 hours after surgery)
Number of subjects: 93
Study 556137 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study 556137 — intervention group
Group type: EXPERIMENTAL
Intervention: Daranide
Number of subjects: 0
Study 556137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31960695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 30
Study 31960695 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation plus hyperproteic oral nutritional supplement (PRS) enriched with beta-hydroxy-beta-methylbutyrate (HMB)
Number of subjects: 30
Study 31897428 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNT001 (FcRn-blocking monoclonal antibody)
Number of subjects: 0
Study 28327503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (140 mL; 800 mg nitrate/day)
Number of subjects: 32
Study 28327503 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (PLA)
Number of subjects: 32
Study 28327503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BR)
Number of subjects: 32
Study 26083948 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin desensitization (AD) with increasing doses of aspirin (60, 125, 325, and 625 mg) followed by 625 mg twice daily for 6 months
Number of subjects: 34
Study 26083948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 26083948 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin desensitization (AD)
Number of subjects: 34
Study 23462833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus Atorvastatin 10 mg
Number of subjects: 30
Study 23462833 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 30
Study 21276586 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg)
Number of subjects: 196
Study 21276586 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg)
Number of subjects: 196
Study 21276586 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus fenofibrate
Number of subjects: 196
Study 21276586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 21276586 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and fenofibrate (combined)
Number of subjects: 196
Study 20183663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Distortions and Maladaptive Beliefs
Number of subjects: 390
Study 20183663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Avoidance
Number of subjects: 390
Study 20183663 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Outlook
Number of subjects: 390
Study 20183663 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution‐Focused Thinking
Number of subjects: 390
Study 20183663 — intervention group
Group type: EXPERIMENTAL
Intervention: Maladaptive cognitions
Number of subjects: 390
Study 20183663 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative cognitions
Number of subjects: 390
Study 16395269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose 100 mg
Number of subjects: 40
Study 16395269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15312371 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative TACE and thymosin alpha(1) (T(alpha1)) treatment (Group A)
Number of subjects: 57
Study 15312371 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative TACE (Group B)
Number of subjects: 57
Study 15312371 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy only (Group C)
Number of subjects: 57
Study 11774937 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H. pylori treatment
Number of subjects: 132
Study 11774937 — intervention group
Group type: COMPARATOR
Intervention: Dietary supplementation with ascorbic acid and/or beta-carotene
Number of subjects: 132
Study 9260798 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (40 mg/day)
Number of subjects: 12
Study 9260798 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1, 300 mg/day)
Number of subjects: 12
Study 9260798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8395916 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 5 mg twice daily before meals
Number of subjects: 12
Study 3805547 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (180 micrograms)
Number of subjects: 10
Study 3805547 — intervention group
Group type: COMPARATOR
Intervention: Placebo (180 micrograms)
Number of subjects: 10
Study 29016880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal hydrocodone ER
Number of subjects: 0
Study 29016880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal hydrocodone powder
Number of subjects: 0
Study 29016880 — intervention group
Group type: EXPERIMENTAL
Intervention: HYD-OF (hydrocodone bitartrate ER capsules)
Number of subjects: 0
Study 29016880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal treatments
Number of subjects: 0
Study 29016880 — intervention group
Group type: COMPARATOR
Intervention: Intact oral hydrocodone ER
Number of subjects: 0
Study 27476641 — intervention group
Group type: EXPERIMENTAL
Intervention: Group discussion
Number of subjects: 60
Study 27476641 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 60
Study 24535134 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 0.6 mg once-daily
Number of subjects: 1331
Study 24535134 — intervention group
Group type: COMPARATOR
Intervention: IFNβ-1a IM 30 μg once-weekly
Number of subjects: 1331
Study 24535134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1331
Study 24084625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602
Study 24084625 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin plus glycoprotein IIb/IIIa inhibitors
Number of subjects: 3602
Study 22204569 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive and Negative Syndrome Scale (PANSS)
Number of subjects: 628
Study 22204569 — intervention group
Group type: EXPERIMENTAL
Intervention: Montgomery‐Asberg Depression Rating Scale (MADRS)
Number of subjects: 628
Study 22204569 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Well‐being Under Neuroleptics Scale Short Form (SWN‐K)
Number of subjects: 628
Study 22204569 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia Objective Functioning Instrument (SOFI)
Number of subjects: 628
Study 22204569 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life Scale (QLS)
Number of subjects: 628
Study 18248876 — intervention group
Group type: COMPARATOR
Intervention: Standard schedule (4 weekly and 5 monthly instillations of 50mg epirubicin/50 ml NaCl)
Number of subjects: 731
Study 18248876 — intervention group
Group type: EXPERIMENTAL
Intervention: Early instillation (same schedule as group 1 with an additional instillation <48 h after TURBT)
Number of subjects: 731
Study 18248876 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance schedule (same schedule as group 1 with additional instillations at 9 and 12 months)
Number of subjects: 731
Study 16393429 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 2848
Study 16393429 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 2848
Study 16393429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2848
Study 14512191 — intervention group
Group type: EXPERIMENTAL
Intervention: RT arm
Number of subjects: 488
Study 14512191 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT arm
Number of subjects: 488
Study 10838648 — intervention group
Group type: EXPERIMENTAL
Intervention: PATCH model intervention (n=310)
Number of subjects: 945
Study 10838648 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=310)
Number of subjects: 945
Study 9357149 — intervention group
Group type: EXPERIMENTAL
Intervention: ILD patients
Number of subjects: 20
Study 9357149 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study 8222677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg)
Number of subjects: 54
Study 8222677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 3108064 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (200 mg) administered 15 and 2 hours before testing
Number of subjects: 8
Study 3108064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30127051 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth and community mobilisation interventions
Number of subjects: 0
Study 30127051 — intervention group
Group type: COMPARATOR
Intervention: Status quo (control group)
Number of subjects: 0
Study 25209524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) provided at discharge
Number of subjects: 816
Study 25209524 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who requested NRT at discharge
Number of subjects: 816
Study 25209524 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with more severe psychiatric symptoms
Number of subjects: 816
Study 25209524 — intervention group
Group type: EXPERIMENTAL
Intervention: Older participants
Number of subjects: 816
Study 24708748 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-negative patients (84% opioids, 76% stimulants, 62% alcohol, 33% marijuana)
Number of subjects: 494
Study 24708748 — intervention group
Group type: COMPARATOR
Intervention: Drug-positive patients
Number of subjects: 494
Study 23594592 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 23594592 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study 21169896 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-10 mg daily)
Number of subjects: 120
Study 21169896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-100 mg daily)
Number of subjects: 120
Study 18420877 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural (0.375% ropivacaine)/general anesthesia (group R)
Number of subjects: 32
Study 18420877 — intervention group
Group type: COMPARATOR
Intervention: Epidural (saline)/general anesthesia (group C)
Number of subjects: 32
Study 17035872 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol-370 (370 mgI/mL)
Number of subjects: 166
Study 17035872 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol-320 (320 mgI/mL)
Number of subjects: 166
Study 14671423 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32
Study 14671423 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon treatment
Number of subjects: 32
Study 14671423 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment followed by balloon treatment
Number of subjects: 32
Study 10696316 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic infiltration into the sub‐Tenon's space through a conjunctival incision (115 eyes)
Number of subjects: 345
Study 10696316 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration into the posterior sub‐Tenon's space (retrobulbar space) through a conjunctival incision (114 eyes)
Number of subjects: 345
Study 10696316 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection into the intra‐Tenon's space (subconjunctival space) without making a conjunctival incision (116 eyes)
Number of subjects: 345
Study 8540712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime 0.5 g
Number of subjects: 0
Study 8540712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime 1.0 g
Number of subjects: 0
Study 8540712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime 2.0 g
Number of subjects: 0
Study 8540712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime 3.0 g
Number of subjects: 0
Study 8540712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime (all doses)
Number of subjects: 0
Study 1902327 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil, a PGE2 derivative, at a dose of 35 micrograms bid
Number of subjects: 12
Study 1902327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6794746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal insulin injection (20 U of regular insulin) into an empty peritoneal cavity
Number of subjects: 9
Study 6794746 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal insulin injection (20 U of regular insulin) followed by 2 litres of 1.5% dextrose dialysate
Number of subjects: 9
Study 6794746 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal insulin injection (20 U of regular insulin) followed by 2 litres of 4.5% dextrose dialysate
Number of subjects: 9
Study 6794746 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal insulin injection (20 U of regular insulin) followed by 20 ml of saline
Number of subjects: 9
Study 28982501 — intervention group
Group type: EXPERIMENTAL
Intervention: PA pressure-guided management
Number of subjects: 456
Study 28982501 — intervention group
Group type: EXPERIMENTAL
Intervention: PA pressure-guided management in patients tolerating GDMT
Number of subjects: 456
Study 28982501 — intervention group
Group type: EXPERIMENTAL
Intervention: PA pressure-guided management in patients receiving both components of optimal GDMT
Number of subjects: 456
Study 25644760 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin plus albumin (TERLI group)
Number of subjects: 49
Study 25644760 — intervention group
Group type: COMPARATOR
Intervention: Midodrine and octreotide plus albumin (MID/OCT group)
Number of subjects: 49
Study 23426978 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus 10 mg/day
Number of subjects: 25
Study 20656527 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral alar base cinch suture
Number of subjects: 35
Study 20656527 — intervention group
Group type: COMPARATOR
Intervention: Classic intraoral suture
Number of subjects: 35
Study 19413826 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic Laryngeal Mask Airway (cLMA)
Number of subjects: 5
Study 19413826 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 5
Study 19413826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 5
Study 19413826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combitube (CT)
Number of subjects: 5
Study 19413826 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 5
Study 19413826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal Intubation (TI)
Number of subjects: 5
Study 18062848 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude-congruent in-group norm in high uncertainty condition
Number of subjects: 189
Study 18062848 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude-incongruent in-group norm in high uncertainty condition
Number of subjects: 189
Study 18062848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous in-group norm in high uncertainty condition
Number of subjects: 189
Study 18062848 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude-congruent in-group norm in low uncertainty condition
Number of subjects: 189
Study 18062848 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude-incongruent in-group norm in low uncertainty condition
Number of subjects: 189
Study 18062848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous in-group norm in low uncertainty condition
Number of subjects: 189
Study 16170894 — intervention group
Group type: EXPERIMENTAL
Intervention: (166) HO-DOTMP plus melphalan
Number of subjects: 0
Study 16170894 — intervention group
Group type: COMPARATOR
Intervention: Melphalan alone
Number of subjects: 0
Study 11717214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol anesthesia (n = 6)
Number of subjects: 12
Study 11717214 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anesthesia with desflurane (n = 6)
Number of subjects: 12
Study 11717214 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anesthesia types (propofol and desflurane)
Number of subjects: 12
Study 9159421 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of gynaecological disorders including measurement of hormone concentrations, cervical cytology, and pelvic ultrasound scan.
Number of subjects: 100
Study 8241913 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 1806
Study 8241913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1806
Study 3662591 — intervention group
Group type: EXPERIMENTAL
Intervention: Green light phototherapy (350‐650 nm)
Number of subjects: 262
Study 3662591 — intervention group
Group type: COMPARATOR
Intervention: Blue light phototherapy (300‐600 nm)
Number of subjects: 262
Study 29641671 — intervention group
Group type: EXPERIMENTAL
Intervention: Local incision analgesia (LIA) with ropivacaine and postoperative analgesia pump
Number of subjects: 60
Study 29641671 — intervention group
Group type: EXPERIMENTAL
Intervention: Local incision analgesia (LIA)
Number of subjects: 60